STUDY OF THE EFFICACY, SAFETY AND QUALITY OF LIFE AFTER TOOKAD® SOLUBLE VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR MINIMALLY INVASIVE TREATMENT OF LOCALIZED PROSTATE CANCER.

Recruitment & Eligibility

Sex: Male

Target Recruitment: 18

Inclusion Criteria

Subjects will be eligible for inclusion in the study if all of the following criteria are met:
Histologically proven localized prostate carcinoma diagnosed using available prostate biopsy showing:
Gleason 3+3 Gleason 3+4 is acceptable provided it is not present in more than 2 cores and no more than 50% cancer in any core.
Clinical stage up to cT2a – N0/Nx – M0/Mx.
Prostate volume ≥ 25 cc and ≤ 70 cc.
Serum prostate-specific antigen (PSA) < 20 ng/mL.
Male subjects aged 18 years or older.
Signed Informed Consent Form by the patient.

Exclusion Criteria

Subjects will not be eligible for the study if meeting any of the following criteria:
Unwillingness to accept the treatment.
Any prior or current treatment for prostate cancer, including surgery, radiation therapy
(external or brachytherapy) or chemotherapy.
Any surgical intervention for benign prostatic hypertrophy.
Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure.
Life expectancy less than 10 years.
Participation in another clinical study involving an investigational product within 1 month before study entry.
Subject unable to understand the patient’s informed consent document, to give consent voluntarily or to complete the study tasks, especially unable to understand and fulfill the health-related QoL questionnaire. Subject in custody and or in residence in a nursing home or rehabilitation facility.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily). - ACCE

Phase 1

SCHERING-PLOUGH

Updated 6/30/2019

To the effect of IDC products on dark spots on face and neck.

CompletedPhase 4

Glenmark Pharmaceuticals Ltd

Updated 11/24/2021

To assess the efficacy of anti-wrinkle products.

CompletedPhase 4

Glenmark Pharmaceuticals Limited

Updated 11/24/2021

The comparison of 2 types of heparin ( unfractionated vs low molecular weight heparin) in patients with stroke due to atrial fibrillatio

Phase 2

Shiraz University of Medical Scienses

Updated 2/22/2018

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Phase 1

ovartis Pharma AG

Updated 3/2/2022

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Phase 1

ovartis Pharma AG

Updated 7/15/2024

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Phase 1

ovartis Pharma AG

Updated 1/9/2023

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Phase 1

ovartis Pharma AG

Updated 1/9/2023

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Phase 1

ovartis Pharma AG

Updated 2/19/2024

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

RecruitingPhase 1

ovartis Pharma AG

Updated 8/21/2024

STUDY OF THE EFFICACY, SAFETY AND QUALITY OF LIFE AFTER TOOKAD® SOLUBLE VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR MINIMALLY INVASIVE TREATMENT OF LOCALIZED PROSTATE CANCER.

Recruitment & Eligibility

Study & Design

Related Trials

A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily). - ACCE

To the effect of IDC products on dark spots on face and neck.

To assess the efficacy of anti-wrinkle products.

The comparison of 2 types of heparin ( unfractionated vs low molecular weight heparin) in patients with stroke due to atrial fibrillatio

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

Clinical Trial Alerts

Clinical Trial Alerts